Site search

Clear filter
2860 results for '' found
A Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 as Adjunctive Therapy in Focal Epilepsy (NCT06612775)
A Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 as Adjunctive Therapy in Focal Epilepsy (NCT06612775)
/
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures (NCT06908356)
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures (NCT06908356)
/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with
/
Expanded Access Program for Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies [DEEs] (NCT06149663)
Expanded Access Program for Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies [DEEs] (NCT06149663)
/
An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults with either classic Absence Epilepsy with or without Eyelid Myoclonia [EEM; Jeavons syndrome], O
An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults with either classic Absence Epilepsy with or without Eyelid Myoclonia [EEM; Jeavons syndrome], O
/
A Phase 1 Study Investigating the Safety, Tumor Uptake, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors (ACTRN12625000268448)
A Phase 1 Study Investigating the Safety, Tumor Uptake, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors (ACTRN12625000268448)
/
A Phase I/II, first-in-human, open-label, dose escalation and indication expansion study of the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of BNT3212 as monot
A Phase I/II, first-in-human, open-label, dose escalation and indication expansion study of the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of BNT3212 as monot
/
A Phase 1a/b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C0902, an Antibody-Drug Conjugate Targeting EGFR MET, Alo
A Phase 1a/b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C0902, an Antibody-Drug Conjugate Targeting EGFR MET, Alo
/
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure Wi
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure Wi
/
A Phase 1a/b Open-Label Master Study of PF-07799544 as a Single-Agent and in Combination with Other Targeted Agents in Participants with BRAF-Mutant Melanoma and Other Solid Tumors (NCT05538130)
A Phase 1a/b Open-Label Master Study of PF-07799544 as a Single-Agent and in Combination with Other Targeted Agents in Participants with BRAF-Mutant Melanoma and Other Solid Tumors (NCT05538130)
/
1 2 3 4 5